Exact Sciences' Q1 Revenues Up on Genzyme Payment; Cuts Loss

Exact Sciences' revenues increased on license fees from Genzyme, while its net loss shrank on lower SG&A expenses.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories